Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Pooled cohort study on height and risk of cancer and cancer death

Wiren, Sara ; Haggstrom, Christel ; Ulmer, Hanno ; Manjer, Jonas LU ; Bjorge, Tone ; Nagel, Gabriele ; Johansen, Dorthe LU ; Hallmans, Goran ; Engeland, Anders and Concin, Hans , et al. (2014) In Cancer Causes and Control 25(2). p.151-159
Abstract
To assess the association between height and risk of cancer and cancer death. The metabolic syndrome and cancer project is a prospective pooled cohort study of 585,928 participants from seven cohorts in Austria, Norway, and Sweden. Hazard ratios (HRs) and 95 % confidence intervals (CIs) for cancer incidence and death were estimated in height categories and per 5-cm increment for each cancer site using Cox proportional hazards model. During a mean follow-up of 12.7 years (SD = 7.2), 38,862 participants were diagnosed with cancer and 13,547 participants died of cancer. Increased height (per 5-cm increment) was associated with an increased overall cancer risk in women, HR 1.07 (95 % CI 1.06-1.09), and in men, HR 1.04 (95 % CI 1.03-1.06). The... (More)
To assess the association between height and risk of cancer and cancer death. The metabolic syndrome and cancer project is a prospective pooled cohort study of 585,928 participants from seven cohorts in Austria, Norway, and Sweden. Hazard ratios (HRs) and 95 % confidence intervals (CIs) for cancer incidence and death were estimated in height categories and per 5-cm increment for each cancer site using Cox proportional hazards model. During a mean follow-up of 12.7 years (SD = 7.2), 38,862 participants were diagnosed with cancer and 13,547 participants died of cancer. Increased height (per 5-cm increment) was associated with an increased overall cancer risk in women, HR 1.07 (95 % CI 1.06-1.09), and in men, HR 1.04 (95 % CI 1.03-1.06). The highest HR was seen for malignant melanoma in women, HR 1.17 (95 % CI 1.11-1.24), and in men HR 1.12 (95 % CI 1.08-1.19). Height was also associated with increased risk of cancer death in women, HR 1.03 (95 % CI 1.01-1.16), and in men, HR 1.03 (95 % CI 1.01-1.05). The highest HR was observed for breast cancer death in postmenopausal women (> 60 years), HR 1.10 (95 % CI 1.00-1.21), and death from renal cell carcinoma in men, HR 1.18 (95 % CI 1.07-1.30). All these associations were independent of body mass index. Height was associated with risk of cancer and cancer death indicating that factors related to height such as hormonal and genetic factors stimulate both cancer development and progression. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Body stature, Body height, Epidemiology, Cancer risk, Cohort study
in
Cancer Causes and Control
volume
25
issue
2
pages
151 - 159
publisher
Springer
external identifiers
  • wos:000330848600002
  • scopus:84893667598
  • pmid:24173535
ISSN
1573-7225
DOI
10.1007/s10552-013-0317-7
language
English
LU publication?
yes
id
84031feb-55b7-4c70-beaa-a710361457c2 (old id 4376373)
date added to LUP
2016-04-01 11:05:17
date last changed
2022-04-05 00:00:01
@article{84031feb-55b7-4c70-beaa-a710361457c2,
  abstract     = {{To assess the association between height and risk of cancer and cancer death. The metabolic syndrome and cancer project is a prospective pooled cohort study of 585,928 participants from seven cohorts in Austria, Norway, and Sweden. Hazard ratios (HRs) and 95 % confidence intervals (CIs) for cancer incidence and death were estimated in height categories and per 5-cm increment for each cancer site using Cox proportional hazards model. During a mean follow-up of 12.7 years (SD = 7.2), 38,862 participants were diagnosed with cancer and 13,547 participants died of cancer. Increased height (per 5-cm increment) was associated with an increased overall cancer risk in women, HR 1.07 (95 % CI 1.06-1.09), and in men, HR 1.04 (95 % CI 1.03-1.06). The highest HR was seen for malignant melanoma in women, HR 1.17 (95 % CI 1.11-1.24), and in men HR 1.12 (95 % CI 1.08-1.19). Height was also associated with increased risk of cancer death in women, HR 1.03 (95 % CI 1.01-1.16), and in men, HR 1.03 (95 % CI 1.01-1.05). The highest HR was observed for breast cancer death in postmenopausal women (> 60 years), HR 1.10 (95 % CI 1.00-1.21), and death from renal cell carcinoma in men, HR 1.18 (95 % CI 1.07-1.30). All these associations were independent of body mass index. Height was associated with risk of cancer and cancer death indicating that factors related to height such as hormonal and genetic factors stimulate both cancer development and progression.}},
  author       = {{Wiren, Sara and Haggstrom, Christel and Ulmer, Hanno and Manjer, Jonas and Bjorge, Tone and Nagel, Gabriele and Johansen, Dorthe and Hallmans, Goran and Engeland, Anders and Concin, Hans and Jonsson, Hakan and Selmer, Randi and Tretli, Steinar and Stocks, Tanja and Stattin, Par}},
  issn         = {{1573-7225}},
  keywords     = {{Body stature; Body height; Epidemiology; Cancer risk; Cohort study}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{151--159}},
  publisher    = {{Springer}},
  series       = {{Cancer Causes and Control}},
  title        = {{Pooled cohort study on height and risk of cancer and cancer death}},
  url          = {{http://dx.doi.org/10.1007/s10552-013-0317-7}},
  doi          = {{10.1007/s10552-013-0317-7}},
  volume       = {{25}},
  year         = {{2014}},
}